Cell Therapy Market Size, Share & Trends Analysis Report By Use-type, By Therapy Type (Autologous, Allogenic), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2021 - 2028

Report Overview

The global cell therapy market size was valued at USD 7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% from 2021 to 2028. The market is majorly driven by the rising number of clinical studies for cell-based therapies. This has resulted in a substantial global investment in research and their clinical translation. The increasing number of ongoing clinical trials can be attributed to the presence of government and private funding agencies that are constantly offering grants to support projects across various stages of clinical trials.

In addition, the field of regenerative medicine is witnessing series of advancements, further expected to offer effective treatment solutions for chronic ailments. Several companies in the growing markets, such as Canada, are at the forefront, striving to capitalize on the untapped potential of the market for cell therapy. For example, RepliCel is investing in multiple projects in regenerative medicine. For instance, in February 2021, the company announced plans for the commercialization and clinical testing of 3 additional technologies in Japan. These include 2 cell-based therapies - one for skin rejuvenation and the other for tendon regeneration.

Moreover, the gradual emergence of new technologies to support the development of advanced therapies has aided in market growth. The introduction of proprietary cell lines is considered as the primary means by which a single product can be exploited for the production of a robust portfolio of candidates. For example, Immunicum employs Chimeric Antigen Receptor T cell (CAR-T) expansion, dendritic cell neoantigen presentation technology, and T-cell primers to advance their product line for immuno-oncology.

Furthermore, direct cell reprogramming has received significant attention as a novel therapeutic strategy. This can be attributed to its higher efficacy and safety. A privately held company-Fortuna Fix-is strategizing to become the first company to commence clinical use of neural stem cells of patients, which will be produced by direct reprogramming for replacement of lost neuronal tissue in case of neurodegeneration or neurotrauma. Such ongoing activities are anticipated to bolster revenue generation in the future.

With significant efforts being made to curb the COVID-19 outbreak, the market for cell therapy has been impacted to a certain extent. Progress in ongoing research is a concern, as many universities worldwide have slowed down their enrollment process for clinical trials as well as for all other research activities. The market, however, continues to expand with many companies like Novartis providing access to their therapies. In addition, Athersys, Inc.’s MultiStem is considered a highly relevant potential therapy for COVID-19.

Use-type Insights

The research-use segment dominated the market for cell therapy and accounted for the largest revenue share of 60.9% in 2020. The stem cells are majorly being used for research projects, which in turn, has led to a large revenue share for the research-use segment. The region is expected to continue its dominance from 2021 to 2028. Cell-based therapies hold great potential for replacing, repairing, restoring, or regenerating damaged tissues, cells, and organs. Researchers are making huge investments in the development of such effective and safe treatments as an alternative to conventional treatment strategies.

Mesenchymal Stem Cells (MSCs) have the potential to address several clinical implications, including moderation of the immune system. Thus, the interest of professionals in employing MSC-based therapy in the management of COVID-19 has spiked in 2020. This can be attributed to the fact that MSCs lack Angiotensin-converting Enzyme-2 (ACE2) receptor. This receptor observes a wide distribution over the human cell surface and is required by coronaviruses for entry into host cells. This property ensures that MSCs, if injected into host cells, have the ability to attain immunomodulatory effects without being affected by the coronavirus.

The clinical-use segment is expected to grow at a gradual rate of 13.4% through the forecast period owing to the less penetration of this segment. However, few cell therapies are approved for clinical applications such as CARTISTEM, Invossa, MACI, Epicel, Cellgram-AMI, Cupistem, Cellistem IC, GINTUIT, Prochymal, and Imlygic, and which is anticipated to encourage the companies to invest in this segment.

Therapy Type Insights

The autologous therapies segment dominated the cell therapy market and accounted for the largest revenue share of 53.2% in 2020. The segment is expected to maintain its dominance during the forecast period. This can be attributed to several advantages associated with autologous transplants such as easy availability, no need to identify an HLA-matched donor, lower risk of life-threatening complications, no risk of GVHD, and no necessity of immunosuppressive therapy. In addition, autologous therapies are affordable when compared to allogenic therapies which can be further attributed to segment growth.

The allogenic therapies segment is expected to witness comparatively slow growth through 2021 to 2028 owing to the high cost associated with allogenic transplants and relatively lower relapse rates. However, growth in cell banking and companies' shift towards the development of allogenic therapy products is driving the market for cell therapy.

Regional Insights

North America is estimated to hold the largest market share of 52.7% in 2020. The large share of the region can be attributed to the presence of a substantial number of centers and institutes that are engaged in R&D pertaining to stem cell therapy. Out of the 8such leading universities throughout the world, 5 are U.S.-based institutes, including Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Harvard Stem Cell Institute, Harvard University, and Yale Stem Cell Center.

In Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.52% over the forecast period. The rising investment by the developers and consumers in educating themselves for advanced medicinal therapies is anticipated to boost the revenue generated from the developing economies of this region. There are several stem cell consortiums in Asian countries, which aim at ensuring ordinated and focused R&D programs. Moreover, patients from western countries are observed to migrate to Asian countries for treatment, owing to the flexible legal framework.

Key Companies & Market Share Insights

Companies are receiving U.S. FDA approvals for their stem cell therapy for various diseases and infections. For instance, in September 2020, FDA granted Investigational New Drug approval to Stemedica Cell Technologies, Inc. for conducting phase II trials for intravenously administered allogeneic MSCs in covid-19 patients. Ischemic-tolerant MSCs have several properties that make them attractive novel biological therapy for COVID-19 such as its immunomodulatory effects, low immunogenicity, and capacity for suppressing excessive pro-inflammatory responses. Some of the prominent players in the cell therapy market include:

• Kolon TissueGene, Inc.

• Anterogen Co., Ltd.

• JCR Pharmaceuticals Co., Ltd. 

• Castle Creek Biosciences, Inc.

• The Future of Biotechnology, MEDIPOST

• Osiris Therapeutics, Inc.

• PHARMICELL Co., Ltd

• Tameika Cell Technologies, Inc.

• Cells for Cells

• NuVasive, Inc.

• Vericel Corporation

• Celgene Corporation

Cell Therapy Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global cell therapy market on the basis of use-type, therapy type, and region 

• Use-type Outlook (Revenue, USD Million, 2017 - 2028)

  • Clinical-use

    • By Therapeutic Area

      • Malignancies

      • Muscoskeletal Disorders

      • Autoimmune Disorders

      • Dermatology

      • Others

    • By Cell Type

      • Stem Cell Therapies

        • BM, Blood, & Umbilical cord-derived Stem Cells

        • Adipose-derived cells

        • Others

      • Non-stem Cell Therapies

  • Research-use

• Therapy Type Outlook (Revenue, USD Million, 2017 - 2028)

  • Allogenic Therapies

  • Autologous Therapies

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

  • Middle East & Africa

    • South Africa